UnitedHealth Group Incorporated (UNH · NYSE)

UnitedHealth Group beat estimates in all of its last four quarters, most recently reporting Q2 EPS of $6.38 versus $4.94 expected (a 29.1% beat) alongside a raised 2026 outlook, though quarterly revenue has been essentially flat sequentially at $112.03B and revenue growth over the trailing year was just 0.4% against 61.5% earnings growth. The stock closed at $376.90, down 6.6% over three months and 13.1% below its 52-week high, yet still 7.6% above its 200-day moving average, with an analyst target of $481.72. Margins remain thin — 3.1% profit and 7.1% operating on $450.53B TTM revenue — while leverage stands at 2.7x debt/EBITDA with $73.33B total debt against $28.59B cash, and quarterly FCF of $10.25B. A class-action lawsuit alleging the company used an AI tool with a 90% error rate to deny post-acute care to Medicare Advantage patients is a pending headline risk.